In this phase of the SUISSE MPC2 study (NCT05534269), measurable data from 10 female patients were included, with a 6-month follow up window, following the injection of the tissue-engineered product into the urethal muscle.
The study aims to assess the safety and efficacy of MUVON Therapeutics AG’s Muscle Precursor Cell (MPC)-based therapy to treat Stress Urinary Incontinence (SUI), a condition where there is involuntary leakage of urine during activities that put pressure on the bladder, for example, laughing, coughing, or lifting heavy weights. Such a condition occurs due to weakened muscles and tissues that support the bladder, preventing the bladder from holding urine during physical stress.
